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Abstract
Invasive fungal infections (IFIs) caused by ﬁlamentous fungi still have high rates of mortality, associated with difﬁculties in early detection
of the infection and therapeutic limitations. Consequently, a useful approach is to prevent patients at risk of fungal infection from
coming into contact with conidia of Aspergillus and other mould species. This document describes the recommendations for preventing
IFI caused by ﬁlamentous fungi worked out by Spanish experts from different medical and professional ﬁelds. The article reviews
the incidence of IFI in different risk populations, and questions related to environmental measures for prevention, control of hospital
infections, additional procedures for prevention, prevention of IFI outside of hospital facilities and antifungal prophylaxis are also
analysed.
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Introduction
Invasive fungal infection (IFI) caused by ﬁlamentous fungi,
especially invasive aspergillosis (IA), has become a high-preva-
lence infection in some groups of patients with predisposing
factors. Aspergillus conidia and those of other species of ﬁla-
mentous fungi are found in suspension in the air, and are
therefore inhaled continuously and frequently colonize body
surfaces [1].
IFI continues to cause high mortality, partly as a conse-
quence of the difﬁculties in early diagnosis, and partly
because of therapeutic limitations. Therefore, one of the
most appropriate strategies is to prevent patients with risk
factors from coming into contact with the conidia of Aspergil-
lus and other species of ﬁlamentous fungi [2,3].
The Medical Mycology Study Group (GEMICOMED) of
the Spanish Society of Infectious Diseases and Clinical Micro-
biology (SEIMC) considered that it was necessary to draw up
a document with recommendations on the prevention of IFI
caused by ﬁlamentous fungi, to answer the clinical questions
that arise in everyday practice. With this in mind, experts
from different study groups and scientiﬁc societies belonging
to different medical and professional specialties involved in
the control of IFI were invited to participate.
The document is divided into six blocks. The ﬁrst block
includes a brief revision of the epidemiology of IFI, with the
deﬁnition of populations at risk according to the incidence of
the infection. Following this, there are ﬁve blocks with ques-
tions, answers, and levels of recommendations. These ﬁve
blocks are:
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1 Environmental preventive measures.
2 Control measures for hospital infections.
3 Special and additional preventive measures.
4 Preventive measures outside of the hospital.
5 Pharmacological prophylaxis.
The object of the experts was to draw up a practical docu-
ment, with the aim of answering all of the questions faced by
health professionals when designing IFI prevention strategies.
In Table 1, the levels of recommendation used are deﬁned.
In Table 2, the answers to questions posed are included with
their corresponding levels of evidence, according to speciﬁc
recommendations made by experts.
Deﬁnition of risk populations according to
the prevalence of IA and other mycoses
caused by ﬁlamentous fungi
From the beginning of the 1990s, an increase in the fre-
quency of IA has been observed [4]. The alterations in host
defence that favour the presence of these infections are very
varied, although, in general terms, three types may be distin-
guished: neutropenia, deﬁciencies in phagocytosis, and altera-
tions in cell immunity [5].
Therefore, the populations at risk for IA are as follows:..
First, there are neutropenic patients (<500 neutrophils/mm3
for >10 days), such as those who undergo chemotherapy for
acute myeloid leukaemia (AML) or myelodysplastic syndrome
(MDS), in which the incidence of aspergillosis is between
10% and 24% [3,6]. Furthermore, patients undergoing alloge-
neic transplant of blood stem cells [2,7,8] are seen to have
an incidence of aspergillosis of 5–8% with haploidentical
donors and of 10–25% with non-related donors.
It must be noted that, rather than the absolute number of
IFIs, what is increasing is the number of patients at high risk
of suffering these infections and, consequently, the consump-
tion of antifungals used for empirical treatment and prophy-
laxis. The increase in the number of patients at risk is
attributable to the greater use of chemotherapy for the
treatment of several diseases, the increase in the number of
transplants, and the use of new immunosuppressants that
stimulate the appearance of these infections. Furthermore, a
change is taking place in the population of patients at risk.
The reduction in the period of neutropenia, achieved by the
use of colony-stimulating factors or new transplant tech-
niques, such as non-myeloablative techniques, seems to have
reduced the role of neutropenia as a risk factor for IFI.
However, the greater number of non-related donor or
umbilical cord transplants has increased the number of post-
transplant infections, mainly with regard to graft-versus-host
disease (GVHD) and its treatment [9–11]. The risk factors
related to the late presentation of IA are the administration
of immunosupressants that reduce the number of T or
CD34 lymphocytes or steroids, neutropenia with lymphope-
nia, GVHD, and cytomegalovirus (CMV) infection [8]. How-
ever, the use of new types of antifungal prophylaxis in these
high-risk haematological patients is decreasing the incidence
of infection in this group [12].
Another group at high-risk for IA are patients undergoing
solid organ transplantation. IA presents during the ﬁrst year
post-transplantation, and its incidence varies with the type of
graft; it is more frequent for lung, heart, gut and liver trans-
plants [13–15]. In Spain, the prevalence of IA in solid organ
transplant patients has decreased by <3% with the use of
prophylaxis [14].
There is a heterogeneous group of diseases in which IA
has been described with greater frequency. Notable among
these is chronic granulomatous disease, with an estimated
incidence of 0.1 fungal infections per patient per year, even if
interferon-c [16] is administered; IA is the main cause of
death in this group [17]. Another group at risk comprises
patients with AIDS, but, with the use of high-efﬁcacy retrovi-
rals, IA is no longer a frequent disease in this population. IA
may be diagnosed in patients without retroviral treatment
with a CD4 count of <100/lL and neutropenia, and being
treated with steroids [2].
During recent years, an increasing incidence of IFI has
been documented in other kinds of patient, such as those
with chronic obstructive pulmonary disease (COPD), espe-
cially those receiving chronic treatment with steroids [18–
23], patients with cirrhosis [24], critical patients [25–30], and
patients who have undergone major surgery, usually of the
heart [31,32]. The incidence of IA in patients with COPD is
still unknown, as are its epidemiological characteristics. A
decade ago, several not very representative studies were
TABLE 1. Classiﬁcation of the recommended measures to
prevent invasive fungal infections according to levels of evi-
dence
Categories of
evidence Deﬁnition
Category IA Sound evidence supported by well-designed experimental,
clinical or epidemiological studies. Must always be
implemented
Category IB Sound evidence supported by experimental, clinical or
epidemiological studies or sound theoretical evidence.
Must be implemented in most cases
Category IC Required by state or autonomous laws or included in
a national or European standard of application
Category II Moderate evidence supported by clinical or epidemiological
studies or theoretical evidence. Must be implemented in
some cases
Not resolved No recommendation made, as there is insufﬁcient evidence
or no consensus
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TABLE 2. Summary of speciﬁc recommendations made by a panel of experts to prevent invasive fungal infections (IFIs)
caused by ﬁlamentous fungi
Type of measure Question Recommendation Level of evidence
Environmental
prevention measures
What is the usual spore
concentration in hospital air?
Studies must be carried out in each centre to determine the normal concentration
and detect signiﬁcant increases. Counts above 25 CFU/m3 can be considered to
bevery high
II
What speciﬁcations must
protected air facilities comply
with?
They must be separate from the rest of the hospital, and possess continuous
air-conditioning through absolute HEPA ﬁlters with at least 12 complete air
changes per hour
IA
What hospital areas should
have protected air?
Protected rooms for patients with severe immunodeﬁciency and operating theatres.
Other facilities, such as the ICUs, must have at least one positive-pressure system
IA
How should the quality of
protected air be analysed?
Some autonomous institutions and communities recommend regular determination
of the number of environmental conidia of ﬁlamentous fungi. According
to UNE100713, as a supplementary test it is possible to use counts of particles
per unit volume of air (Table 4)
IC
When should
microbiological determinations
of air be performed?
It is advisable to carry out environmental cultures when required by current
legislation and when there are cases of IFI caused by aerial fungi or when
refurbishment and maintenance works are being carried out. However,
some experts recommend carrying out cultures on a regular basis to verify
the proper operation of the facility, both in operating theatres and in
protected rooms
IA
What is the acceptable
concentration of fungi (CFU) in
protected air?
The limit of CFU/m3of air is 0.5, which means, as a maximum, it is possible to
detect one colony of ﬁlamentous fungi in a sample of 2 m3 of air
IC
What is the acceptable
concentration of fungi (CFU) in
unprotected hospital air?
Figures vary according to the study consulted. Under normal conditions, this should
be below 25 CFU/m3
II
Do routine microbiological
surveillance cultures have any
additional value?
They may be useful to determine the integrity of the ﬁlters of protected areas,
although ﬁlter maintenance is more important. They may be helpful to determine
the presence of unexpected contamination foci in centres that do not have
adequate installations. They make it possible to have historical measurements to
use for comparison purposes
II
Should microbiological
cultures of hospital water be
performed?
There are no recommendations as to acceptable levels of conidia in water, so
surveillance cultures of hospital water are not recommended
Not resolved
Who should make the
decision to act on the
basis of environmental
measurements?
Every health institution should have a Committee to Monitor and Evaluate the Risk
of Infection to coordinate the measures necessary in each centre
IC
Hospital infection
prevention measures
What health education
measures are recommended?
Health personnel who care for patients at risk for IFI must receive speciﬁc training
on epidemiology, mechanisms of transmission, and measures to control and prevent
infection
II
What speciﬁc surveillance
methods are recommended?
Instituting a registry of cases of IFI so as to detect increases in incidence II
Should surveillance
cultures be performed of
patients at risk, materials, or
equipment?
They have been shown to have no predictive value, so they are not recommended IB
What patients should be
hospitalized in protected
rooms?
Patients with allogeneic transplants of haematopoietic stem cells or with severe
neutropenia (<100 cells/mm3) of more than 1 week’s duration
IC
What cleaning and
disinfection measures are
recommended for protected
areas?
These should be cleaned at least twice a day and whenever there is accidental liquid
spillage, with conventional cleaning products. Regular preventive sanitization must
be performed with H2O2 or ozone
IC
Can patients at risk be
moved around the hospital?
Exits from protected areas must be restricted as much as possible. If they are
unavoidable, a protective FFP3 breathing mask must be used, and any areas where
refurbishment or repair works are being carried out must be avoided
II
Should any additional
standard precautions be taken
to decrease the risk of IFI?
There are no data, but usual precautions are recommended, such as exclusive
clothing, gloves, masks, and hand-washing
Not resolved
Are there any
recommendations on the
personal hygiene of admitted
patients who are at risk for IFI?
Single-use sponges must be used. Showering or bathing are not recommended,
owing to the presence of conidia. There are no data on the preventive efﬁcacy of
tap ﬁlters
IB
What are the
recommendations if there are
cases or an outbreak of IFI?
Determine whether it is of hospital origin. Carry out cultures of patients and the
environment. Determine the status of the isolation facilities. Perform molecular
typing of isolated strains
IB
Special and additional
prevention measures
What recommendations
should be made in the case of
patients with some risk of IFI
hospitalized in unprotected
areas with ongoing
refurbishment or structural work?
There are no recommendations, but conidial counts may help. Concentrations
>25 CFU/m3 may be considered high and potentially associated with an increase
of risk of IFI
II
Should hospital structural work be
classiﬁed according to its
risk regarding IFI?
It is necessary to stratify the work that may be carried out within and outside the
hospital and adapt preventive measures to the degree of risk (Tables 6 and 7)
IC
What must be done to
prevent IFI when structural
work is being carried out in
a hospital?
A multidisciplinary group must be created as a part of the Works Committee, to
work together with the Committee to Monitor and Evaluate the Risk of Infection
IC
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published in which chronic respiratory conditions were a risk
factor for 1–1.5% of cases [18,20–22]. However, recent stud-
ies indicate that the presence of COPD may be a risk factor
for IA in up to 20% of cases. This percentage increases in
the case of critically ill patients suffering from non-neoplastic
respiratory disease, where 42% of cases of IA have been
observed in patients with COPD, and it has therefore been
deﬁned as an independent risk factor [19,20,23,25]. For
patients with cirrhosis, no reliable data are available, but one
study determined that 7% of critically ill patients with IA
could suffer from cirrhosis [23].
The frequency of IA in other critical patients seems to be
underestimated, as it has been observed on autopsy that
2.7% of patients who die in intensive-care units (ICUs) have
IA, and that 30% of these were neither diagnosed with nor
treated for this condition [24,33]. The prevalence of IA in
critical patients ranged from 0.3% to 5.5%, according to the
populations studied, with or without associated haematologi-
cal disease [23,28,30,34]. The frequency with which Aspergil-
lus has been isolated in critical patients has also been
analysed, and found to range from 0.33% to 1.1% [25,35].
Finally, postsurgical patients represent another population
at risk of developing IA. In a recent review of the literature
that included more than 500 patients, heart (32%), dental
(19%), eye (17%) and chest (10%) operations were those
most frequently associated with IA, although the infection
rate is unknown in these populations [32], with the excep-
tion of fungal endocarditis after heart surgery, which affects
0.1% of the total number of valve replacements, Aspergillus
being the cause of 25% of these episodes [31].
With reference to infections caused by other ﬁlamentous
fungi, an increase in the incidence of several species, such as
those affecting the oral mucosa, Scedosporium spp. and Fusari-
um spp., has been observed. However, the incidence of these
infections is much lower than that of IA, and there are no
speciﬁc preventive measures for these emerging species,
although, probably, most of the concepts developed for IA
prevention are applicable to mycosis caused by these other
fungi [3,36].
Regarding environmental factors that affect the incidence
of IFI, it must be noted that Aspergillus spp. and other spe-
cies of fungi are ubiquitous environmental fungi. Hundreds
of conidia are inhaled daily, and, in most cases, are elimi-
nated without clinical consequences [1,37]. However, in the
case of persons with anatomical or immune alterations,
inhalation may cause infection [38]. Furthermore, there is a
certain geographical inﬂuence affecting fungal exposure,
which could explain the greater incidence of IA in some
centres than in others, in patients with the same risk fac-
tors [39].
Construction and refurbishment works in a hospital or
nearby areas, together with colonization of air conduits and
contaminated water, may be the main sources of hospital
Aspergillus infections [40–43]. However, hospital infections
could be infrequent, as most infections are sporadic, and it is
difﬁcult to determine whether they were acquired within or
outside hospitals. Two facts could support the possibility of
an extra-hospital source of IA, although there is no clear evi-
dence on this. First, when it presents during the post-trans-
plantation phase of granulopenia, the patient is usually in an
TABLE 2. (Continued)
Type of measure Question Recommendation Level of evidence
Should any additional
recommendations be made
with reference to the work
plans to prevent IFI?
A table diagram must be drawn up (similar to Table 7) with the measures to be
taken according to the type of work and the risk of infection
IC
Prevention measures
outside the hospital
In which patients should
measures be taken to prevent
community IFI?
In neutropenic patients who return home during the period of aplasia. Risk increases
with a central venous catheter, ambulatory parenteral nutrition, yeast colonization,
or immunosuppressive treatment
IB
What are the general
recommendations for these
ambulatory patients?
Avoid areas with structural work, gardening work, a lot of dust, and public baths
and bathing pools. If these are unavoidable, an FFP3 mask should be used
IC
What recommendations should
be given related to their homes
and everyday activities?
Increase hygienic measures in the home, frequent hand-washing, and the use of
individual sponges. Limit contact with pets. Avoid contact with ornamental plants
and ﬂuffy toys. In the case of paediatric patients, toys must be cleaned
IC
Are there any recommendations
on smoking?
Smoking tobacco, marihuana and cannabis must be forbidden IB
What recommendations are
there related to food?
Spices, tea and herbs for infusion, unpasteurized beer, aromatic herbs, whether fresh
or dry, that have not been cooked for several minutes, blue cheeses or those that
have undergone prolonged fungal fermentation processes must be forbidden, owing
to their high conidial content
IC
Can any further
recommendations be made
related to the patient’s home?
There are no deﬁnite studies, but cleanliness and control of home air-conditioning
systems are recommended. Avoid carpets and rugs. Do not use a vacuum cleaner
unless it has a HEPA ﬁlter. No home surveillance cultures are recommended, or
ﬁlters on taps
Not resolved
ICU, intensive-care unit.
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isolation chamber with a HEPA ﬁlter, which prevents conidia
inhalation, suggesting that the infection must have originated
from colonization prior to admittance. Second, in cases of
late presentation patients will have been home for months,
which makes us think that preventive measures should be
applied in the homes of these patients.
There are several environmental sources of conidia: the
ground, ornamental plants and ﬂower arrangements, plant
detritus, and the remains of food and water [41]. Few stud-
ies have established a correlation between the concentration
of conidia of Aspergillus in the air and the risk of infection or
colonization. It is evident that, in high-risk patients, concen-
trations as low as 1 CFU/m3 may cause infection [43], which
is why environmental control measures have been proposed.
These measures are difﬁcult to adhere to over prolonged
periods of time, both in hospitals and in patients’ homes.
Therefore, pharmacological prophylaxis is a very useful alter-
native in these high-risk populations.
Last, but not least, there are no recommendations
regarding the incidence rate that would justify the applica-
tion of preventive measures in a population at risk,
although they should be applied in groups at major risk of
suffering an IFI. As we indicated above, the duration of neu-
tropenia and its association with other factors such as
immunosuppressive treatments (steroids, monoclonal anti-
bodies, etc.), which are used mainly for the prevention and
treatment of GVHD, favour the appearance of IA. Further-
more, the main factor associated with the development of
IA in patients with COPD is the use of steroids, especially
high doses (>20 mg/day or cumulative doses of 700 mg)
[19,20]. In the case of critical patients, the association of
several factors such as neutropenia (<500 neutrophils/mm3),
haematological neoplasia and allogeneic transplantation, con-
siderably elevate the risk of IA. Others have a more mod-
erate risk, such as those receiving prolonged corticotherapy
before admittance or autologous transplants, those with
COPD, liver cirrhosis, solid organ tumours or AIDS, and
those receiving lung transplants and treatments with
alemtuzumab or etanercept, as well as concomitant antibac-
terial treatments. Moreover, patients who must be consid-
ered to have increased risk, but less risk than those listed
above, are those with severe burns, lung transplants, corti-
cotherapy for <7 days, ICU stay of >21 days, malnutrition,
and prior heart surgery [11,34]. Finally, the factors associ-
ated with postsurgical IA result from contamination of the
surgical or postsurgical environment with fungi conidia.
There have also been reports of contamination of dialysis
circuits and surgical material (especially prostheses); even
the patients themselves may be the origin of contamination,
owing to shedding from lesions [31,32].
Environmental prevention measures:
architectural design and air/water
installations
What is the normal concentration of ﬁlamentous fungi in
environmental air both inside and outside hospitals?
There is no consensus on the number of CFU/mm3 air that
is normal in the environment, both within and outside hospi-
tals. In Spain, a study was performed in the Community of
Madrid, in which the concentration of Aspergillus in the air
was analysed [44]. The results indicated that there are sea-
sonal variations. In spring, there were lower counts, and in
autumn higher counts (median 1.3 CFU/mm3 versus 12 CFU/
m3). Environmental conditions also inﬂuenced the count of
CFU/m3. The range seen in these counts was 0–85 CFU/m3.
Other authors support the existence of seasonal variations
but have found higher mean counts, varying between 20 and
105 CFU/m3 [45,46].
Within hospitals, the data are equally controversial. How-
ever, it is necessary to distinguish between normal areas of
hospitalization and others, where there must be some level
of protection. The ﬁgures considered to be normal also vary
according to different sources. Unﬁltered air must contain
no more than ﬁve conidia/m3, although other experts accept
between 10 and 25 CFU/m3 [45,47]. However, air ﬁltered
through HEPA ﬁlters with an efﬁciency >95% and with ‡12
air changes per hour must have a count <0.1 CFU/m3. When
measurements were performed in a hospital with HEPA ﬁl-
ters to ﬁlter the air of all the facilities, the results seen in
Table 3 were obtained [48].
Finally, it is worthwhile mentioning a study that analysed
fungal concentrations in a hospital over 10 consecutive years
[49]. The authors found that many more colonies grew when
the dishes were incubated at 25C than when they were
incubated at 37C. Air outside the hospital was sampled 129
times, and the mean count at 25C was 848 CFU/m3 versus
122 CFU/m3 at 37C.
TABLE 3. CFU/m3 in different hospital areas with complete
air treatment with HEPA ﬁlters
Hospital area
CFU/m3 of
fungi
CFU/m3 of
Aspergillus
Hospital entrance 1 0.3
Hospitalization area 5.7 0.7
Unit for haematopoietic stem
cell transplantation
0.04 0
Unit for solid organ transplantation 0 0
Medical ICU 0.7 0
Surgical ICU 1.4 0
Operating theatres 0.6 0
ICU, intensive-care unit.
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In conclusion, the concentration of spores in the air may
vary signiﬁcantly according to: (i) geographical area; (ii)
degree of activity in the area sampled; (iii) temperature,
humidity or airﬂow ﬂuctuations; and (iv) changes in light
intensity. However, in facilities where air is ﬁltered through
HEPA ﬁlters, the number of CFU/m3 decreases to concen-
trations near zero. Therefore, to determine what the usual
concentration of spores in the hospital environment is, it
would be necessary to perform a comprehensive local analy-
sis, which would include areas of the hospital with different
measures of protection, keeping in mind the variables men-
tioned above. A parallel study of air outside the hospital
would help to deﬁne the usual concentrations of spores in
the corresponding geographical area. Below, some recom-
mendations are made with regard to the numbers of conidia
that may be considered normal, according to available stud-
ies.
What is protected air?
Protected air can be deﬁned as the air within a protected
environment. A protected environment is a hospital area
that is as hermetic as possible and has a greater pressure
of air (excess pressure) than surrounding areas, which
means that the air ﬂows from the protected environment
towards the exterior. In operating rooms and in so-called
protected rooms, air treatment must be independent of
that carried out in the rest of the hospital. Air-conditioning
must be continuous, the air must be ﬁltered through abso-
lute HEPA ﬁlters, and there must be a high number of air
exchanges per hour. In the case of ICUs, there are no gen-
eral recommendations, but, at least, the air-conditioning
system must maintain excess air pressure, so that the most
critical areas have a higher pressure than the less critical
ones, and these have a higher pressure than the rest of the
hospital. It is advisable to design independent systems for
each area or sub-area, so that, if there is contamination,
this does not extend and can be easily contained and neu-
tralized [50].
What hospital areas do not need protection?
There are at least two areas that do not need protection,
owing to the low risk of infection: the administration/public
area, and the areas where patients with no risk of IFI are
hospitalized. In the administrative area, the air-conditioning
system may be turned off at night, although this must not
affect the differential pressure in other areas of the hospital,
such as the laboratories, ICUs, isolation rooms, protected
rooms or operating theatres. In the areas where there are
patients with no risk, the excess pressure air-conditioning
system must not be turned off [50,51].
What hospital areas require protection?
The so-called special areas are as follows: (i) protected
rooms; (ii) operating theatres; and (iii) any other area chosen
by the Risk of Infection Evaluation and Control Committee,
such as the ICUs, burn units, oncology and transplantation
units, polyclinics and units where human immunodeﬁciency
virus-positive patients are hospitalized, dialysis units, heart
angiography units, or pharmacy service units where injected
drugs are prepared. For other areas where medium-risk to
high-risk IA patients are hospitalized, such as emergency
rooms, radiology and imaging units, resuscitation units, post-
anaesthesia units, delivery rooms, neonatology areas (non-
critical), ambulatory surgery, nuclear medicine, ultrasound,
laboratories, paediatric and geriatric units, and chronic-care
units, there are no recommendations. The Risk of Infection
Evaluation and Control Committee of each hospital must
evaluate other hospital areas, and state whether they should
be protected. Another special area comprises the isolation
rooms for patients with infections caused by transmissible
microorganisms, the design of which is different from that of
protected areas, as there must be negative pressure in these
areas.
The rooms with a protected environment are for the hos-
pitalization of patients with severe immunodepression, and
the air must be ﬁltered with HEPA ﬁlters, and positive pres-
sure must be maintained in relation to surrounding areas.
The recommended positive pressure is between +2.5 and
+8 Pa in relation to the passages. Air changes ‡12 times an
hour of the total volume of air in the room are recom-
mended. The air that enters the room must be injected at a
minimum speed of 0.25 m/s through a HEPA ﬁlter with
99.97% efﬁcacy for particles ‡0.3 lm. The air that leaves the
room does not require ﬁltration. The ﬂow of ﬁltered air
must be directed towards the patient and then eliminated.
Fig. 1 shows a diagram of a room with a protected environ-
ment [50–52].
The main characteristics of the operating theatres, ICUs
and burn units according to standard UNE100713 are
shown in Table 4. The air must have three ﬁltering stages
with a terminal HEPA ﬁlter. It is to be noted that the qual-
ity of air in the interior of health facilities is speciﬁed in
Standard ISO 14644, on Cleanrooms and Associated Controlled
Environments. Classiﬁcation of Air Cleaning, which deﬁnes the
number of particles in a volume unit of air. Furthermore,
for pharmaceutical environments, it is possible to ﬁnd guide-
lines in the EC Guide to Good Manufacturing Practice. The
inert particles in the air act as vehicles for the transport of
pathogens. Controlling the level of particles in the air is
indispensable to reduce the risk of infection; therefore,
several autonomous legislation systems have adopted these
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recommendations and standards [50–53]. As the size of ﬁla-
mentous fungi spores is in the order of 2.5 lm, a quality of
air below the level of ISO 8 (Table 4) in areas at risk should
be sufﬁcient.
Air ﬁltration through a HEPA ﬁlter is a step in the contain-
ment of pathogen-carrying particles, although not the only
one. There are a series of measures that may be applied to
increase the levels of cleanliness and safety of critical areas:
1 Physical isolation of risk areas from the rest of the hospital.
With this measure, it is possible to prevent a ﬁrst con-
tact, and the risk of pathogens generated outside the
area reaching the controlled area is minimized. Isolation
must be complete, including not only architectural
isolation but also isolation of the air-conditioning installa-
tions.
2 Entry through air-locks. Entering through air-locks increases
the safety of critical areas and adds an intermediate ele-
ment that makes it possible to put into practice other
containment measures, such as changes of shoes or cloth-
ing, and washing and disinfection of hands and utensils.
3 Laminar ﬂow in risk areas. Laminar or unidirectional air-
ﬂow is the greatest form of protection, and is based on a
continuous ﬂow of ultraﬁltrated air, at a uniform speed
(0.36–0.54 m/s), that sweeps uniformly through the criti-
cal area, keeping the environment at ISO 5 (Grade A
GMP). This system is not necessary in protected environ-
ment areas, with the exception of special facilities for the
hospitalization of patients with very severe and unusual
immunodeﬁciencies.
What other factors must be kept in mind when designing
operating theatres, ICUs, and protected rooms?
Several different issues must be considered when designing
these facilities. The material used in the construction of these
critical areas should not shed particulate matter, and should
be easy to clean, ﬁreproof, and resistant to regular disinfec-
tion. The surfaces must be smooth and have as few as possible
joints, cracks and irregularities where dust and particles may
be deposited. Special attention must be given to ease of
cleaning (smooth surfaces, curved joints, and no nooks and
CamaBed
Hygiene
Direction of air flowAir impulsion grid Air expulsion grid
Control point
Corridor
FIG. 1. Diagram of a room with a pro-
tected environment.
TABLE 4. Classiﬁcation of operating theatres and critical-care units according to UNE100713a
High-technology class
1000/M4.5/ISO6
Conventional class
10 000/M5.5/ISO7
Ambulatory patients class
100 000/M6.5/ISO8
ICU and burn
care unit
Temperature (C) 22–26 22–26 22–26 24–26
Relative humidity (%) 45–55 45–55 45–55 45–55
Acoustic level (dB) 40 40 45 40
Air movement (movements/h) Unidirectional and >120 Turbulent and 40 Turbulent and 20 Turbulent and 20
External air 40 ren/h 100% 100% 100%
Airspeed (m/s) 0.3–0.6 0.2–0.3 0.2–0.3 0.2–0.3
Pressure (Pa) +15–20 +15–20 +5 +5
Filters 25% G4 25% G4 25% G4 25% G4
90% F9 90% F9 90% F9 90% F9
99.97 H14 99.97 H14 99.97 H14
Maximum value for particles >0.5 lm 35 200 352 000 3 520 000 –
Maximum value for particles >5 lm 293 2930 29 300 –
Appropriate for: Patients undergoing organ
transplantation, heart surgery,
or orthopaedic surgery with prosthesis
Conventional and emergency,
other surgical operations
Ambulatory ofﬁces and
delivery rooms
–
aIn those hospitals where infected patients are operated on, it is necessary to consider the building of operating theatres where expelled air is ﬁltered through HEPA ﬁlters,
especially if there is air recirculation. Surgery in all immunodepressed patients should be performed in class 1000 operating theatres.
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corners). Especially critical points are wall–ﬂoor joints; these
must be continuous, and the ﬂoor covering must curve up to
meet the wall. There must be a false roof, to separate the con-
trolled inner environment from the environment of the upper
technical space. Windows must not open, to prevent contact
with the exterior environment. Furthermore, the frames must
integrate seamlessly into the surrounding architectural struc-
tures, with no edges, grooves or irregularities. The doors
must be made of inert material, must not shed particulate mat-
ter, and must have smooth surfaces that are easy to clean. No
wood or substances derived from wood must be used. The
edges of the doors must be curved, with smooth lines that
make them easy to clean. The closure systems must have a
minimum number of grooves and irregularities [50–53].
How often and at what level of protection must microbio-
logical air controls be carried out?
There is no consensus on the need for or the frequency of
microbiological controls for rooms in a protected environ-
ment, although some experts recommend them to ensure that
the installations work properly [49,54–56]. Environmental sur-
veillance is recommended when there is a case of IFI caused
by an airborne fungus such as Aspergillus; it is then necessary
to assess the risk resulting from special environmental condi-
tions (repair or refurbishment works), and to determine when
the risk has disappeared [49,54–58]. Furthermore, an increase
in the incidence of IFIs of supposed hospital origin must give
rise to an exhaustive environmental investigation [49,54–58].
In addition, provisions laid down by some of Spain’s self-gov-
erning regions advise carrying out regular microbiological con-
trols in operating theatres. Environmental surveillance is also
recommended immediately before the initial opening of an
operating theatre or after it has undergone repair or refur-
bishment [59–62]. In class 1000 or 10 000 operating theatres
(Table 4) the limit is 0.5 CFU/m3, which means that the maxi-
mum permitted is the detection of one ﬁlamentous fungal col-
ony in an intake of 2 m3 of air, a standard that also may be
applied in other areas with a protected environment.
There are now recommendations from experts that
monthly monitoring of air quality with a laser counter
equipped with an isokinetic probe that analyses the number
and size of particles between 0.3 and 10 lm could be a sub-
stitute marker of the microbiological quality of air. In some
countries, it is recommended that air quality in operating
theatres should be monitored with this type of laser counter
[58]. In any case, this should be considered as a supplemen-
tary technique, for which more research is necessary. It must
also be noted that the particle count does not make it possi-
ble to identify pathogenic microorganisms or establish corre-
lations with isolated patients in outbreaks.
Aspergillus counts in non-protected environmental air are
usually between 10 and 25 CFU/m3. Higher counts may be
considered as abnormal, especially in hospital areas with
unprotected environments where patients at risk for IFI may
be hospitalized. These increases in count usually correlate
with land movements or work on structures, so it is recom-
mended that counts be made if there are any works in pro-
gress nearby [63–66].
Are machines better at performing sample cultures?
Many machines designed for sampling air are not designed
for the control of air quality in protected rooms or operat-
ing theatres, so not all are appropriate. The machines must
comply with a series of speciﬁcations, such as being capable
of sampling an appropriate volume of air in a reasonable time
or before the culture medium dries out (2 m3 in 10 min).
They must be operated by remote control and be easy to
use and clean. The use of sampling methods based on aspira-
tion is recommended, in which air impacts or is ﬁltered or
bubbles through different support media that serve as collec-
tors of particles: porous ﬁlters, agar media, adhesive strips,
or different types of liquid. If conventional Petri dishes are
not used, the cost of the strips or ﬁlters must be consid-
ered, as some are very expensive. Any of the methods used
to monitor air in the operating theatre must be appropriate
for being used near to surgical wounds [67]. These systems
make it possible to identify fungi isolated from the different
support media and to quantify the number of spores present
in a certain volume of aspired air.
Table 5 includes a summary of the most frequently used
machines that are currently available.
TABLE 5. Characteristics of the air-sampling machines
Sampler
Flow
(L/min) Method Plate/Strip/Filter
Andersen Sampler 28.3 Impact through a sieve Standard plate, 90 mm
Biotest RCS 40 Centrifuge impact Strips
Biotest RCS Plusa 50 Centrifuge impact Strips
Biotest HiFlowa 100 Centrifuge impact Strips
Casella
(high volume)b
700 Impact through a slit 150-mm plate
Casella
(low volume)b
30 Impact through a slit Standard plate, 90 mm
Mattson Garvin 28.3 Impact through a slit 150-mm plate
Merck MASc 100 Impact through a sieve Standard plate, 90 mm
Microbio 1 100 Impact through a sieve 55-mm contact plates
Microbio 2 100 Impact through a sieve 55-mm contact plates
Millipore 140 Impact through a sieve Preﬁlled cassette
Negretti 100 Impact through a sieve 55-mm contact plates
New Brunswick 28.3 Impact through a slit 150-mm plate
Sampl’air 86–200 Impact through a sieve Standard plate, 90 mm
Sartorius MD8 42–133 Filtration Gelatin ﬁlters
SAS 90 90 Impact through a sieve 55-mm contact plates
SASb 180 Impact through a sieve 55-mm contact plates
aRemote connection by means of infrared rays.
bRemote connection by cable.
cConnection with a delay of up to 60 min.
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Are there any ofﬁcial regulations or legislation on whether
conidial concentrations should be measured in
environmental air to determine the degree of air control?
As previously indicated, some autonomous legislation has
adapted the UNE or ISO standards for surgical areas [50–52].
Several of Spain’s self-governing regions recommend carrying
out regular surveillance cultures in surgical areas. Some Euro-
pean legislation also recommends carrying out particle counts
with laser counters, together with a count of acceptable parti-
cles according to the type of operating theatre (Table 4).
A guide published by the Spanish Society of Preventive
Medicine recommends carrying out cultures in high-risk
areas at intervals of a maximum of 1 month, as many hospital
centres are located in contaminated urban areas and fre-
quently undergo refurbishment or repair work [68].
According to the experts who drew up these recommen-
dations, performing regular air cultures to assess air quality,
with reference to the presence of fungi, could be recom-
mended in certain cases. It is a useful strategy to detect
problems related to air-conditioning systems of protected
areas (ﬁlter integrity), although the maintenance of these is
more important than sampling, and laser particle counts may
be used as a supplementary technique. Regular cultures may
also help to reveal unexpected contamination foci in centres
whose facilities do not comply with current architectural
recommendations, and make it possible to have historical
series, which are useful for comparison purposes when there
are high levels of contamination.
How should surveillance sampling be performed?
Although air samples, samples from different surfaces and
water samples can all be processed to detect opportunistic
environmental fungi [40,69,70], quantiﬁcation using air sam-
ples is a more direct measure of patient exposure to conidia
in the environment [71]. The total volume of air to be col-
lected may range from 180 to 1080 L, according to the size
of the area to be sampled.
The main areas where the presence of opportunistic fungi
is a concern, and which therefore should be sampled, are
those where high-risk patients are hospitalized, such as
rooms with patients who are to undergo major surgery
(operating theatres), rooms with patients with neutropenia
or, in general, all areas which, for some reason, have been
equipped with HEPA air ﬁlters.
There are also no ﬁxed rules for sampling regularity. Sam-
pling must be regular, so as to provide useful information, but
it must not overload the microbiology laboratory with work.
The most common practice is to take monthly environmental
samples in areas equipped with HEPA ﬁlters. Once air samples
have been collected, the dishes must be sealed and subse-
quently incubated for 5 days at temperatures ranging from
28C to 37C. There may be differences in colony counts
when the dishes are incubated at different temperatures, with
higher counts being seen at lower incubation temperatures,
whereas, at 37C, the only colonies formed are those of fungi
that are capable of growing at human body temperature, and
are therefore potential pathogens [49].
What is the contribution of water?
Different studies have shown that hospital water contains
fungi [40,69,72–76]. The main conclusion of these studies is
that there are ﬁlamentous fungi in hospital water distribution
systems, and that the same species can be found in the piped
water outside the hospital. Furthermore, it has been demon-
strated by means of molecular epidemiology that strains iso-
lated from water have been the cause of IFIs. Fungi form
part of the hospital water bioﬁlm, and an increased concen-
tration of conidia is detected in the bathrooms in compari-
son with rooms and reception areas. Furthermore, there is a
correlation between the species isolated from water and
those isolated from air within hospitals. There is no seasonal
variation in the concentration of conidia in water within or
outside hospitals, and the older the building, the greater the
concentration of spores in the water.
It is also known that the concentration of ﬁlamentous fun-
gal spores depends on the source of the water. Under-
ground water is usually not contaminated, and surface water
always is. It must be noted that the treatment undergone by
water to make it of drinking water quality does not seem to
affect conidia, and that only daily cleaning and disinfection of
bathrooms and protected rooms, including walls and ﬂoors,
signiﬁcantly reduces spore concentration/m3. There is no
consensus as to what conidial concentration is acceptable, so
surveillance cultures are not recommended.
Who makes the decision to take steps to prevent IFI?
Current legislation, like international standards and expert
recommendations, state that every health institution should
have an Infection Control and Risk Assessment Committee
in charge of coordinating the necessary control measures in
each institution, according to their activity, location and the
incidence of infection.
Hospital infection control measures
Measures for the prevention and control of IFI in high-risk
patients in health institutions have not been detailed, up to
the present time, in a speciﬁc guide on the subject. The most
frequently followed recommendations can be found in guides
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that deal with the prevention of opportunistic diseases in
haematopoietic transplant recipients [77], with hospital infec-
tions related to construction or repair work in health institu-
tions [78], with the control of infections transmitted by the
environment [79], and, ﬁnally, with the prevention of pneu-
monia associated with mechanical ventilation or pneumonia
associated with intensive care [80]. The scientiﬁc rigour and
value of all these recommendations mean that they contain
much excellent information for drawing up this guide. There-
fore, many of the answers to the questions posed in this
document are based on these recommendations.
What health education measures are necessary for the
prevention of IFIs?
Health personnel who care for patients at high risk for IFI
must receive speciﬁc training on epidemiology, mechanisms
of transmission, and methods of infection prevention and
control. Furthermore, it is advisable to involve these person-
nel in the appropriate implementation of these recommenda-
tions or when putting into place any special or additional
measures, using markers or techniques for improving health-
care [79,80].
What surveillance methods for detection of hospital IFIs
should be carried out and what patients are the object of
these measures?
For patients with a severe state of immunodepression and a
high risk for IA (see the ﬁrst part of the document), there
must be a high rate of suspicion of the disease in cases of
symptoms or signs of pulmonary involvement [8,10,81–86].
Other, more susceptible, patients are those who have under-
gone haematopoietic organ transplants; rather less suscepti-
ble patients are those who have haematological neoplasias
and are undergoing chemotherapy, those with solid organ
transplants, and those undergoing prolonged treatment with
high doses of steroids.
The health professionals in charge of surveillance and con-
trol of infections in health institutions must have a permanent
system for registering new cases of IFI, and therefore require
precise and immediate information on the detection of Asper-
gillus and other fungi in respiratory samples. Furthermore, it is
necessary to perform a regular review of microbiological, nec-
ropsy or histopathological data suggestive of infection [79,80].
Routine molecular tests or antigen detection tests and
X-ray studies for the diagnosis of presumed disease may
markedly decrease the number of new proven cases of IA
[87,88]. Surveillance of IA incidence by means of these new
diagnostic tests is still an unresolved issue.
The deﬁnitions proposed by the European Organization
for Research and Treatment of Cancer/National Institute of
Allergy and Infectious Diseases, Mycoses Study Group (EO-
RTC/MSG) for the diagnosis of proven, probable or possible
aspergillosis must be used to detect new cases of IFI in high-
risk hospitalized patients [89].
The systematic practice of carrying out surveillance cul-
tures of respiratory samples for the detection of Aspergillus is
not recommended in any type of hospital population, includ-
ing patients at high risk for IA [90,91]. Likewise, regular cul-
ture of material from the equipment or surfaces in special
areas for the hospitalization of patients with transplants of
haematopoietic organs is not recommended [77,91].
What patients should be hospitalized in areas with a
protected environment and for how long?
However, as most hospitalized patients have a minimum risk
of IFI, and exposure to conidia is extremely difﬁcult to avoid,
preventive measures should be limited to populations at
greater risk of contracting this disease. Recommendations
limit the use of rooms with air-conditioning and protected
air environments to patients with allogeneic transplants of
haematopoietic stem cells or with severe neutropenia
(<100 cells/mm3) of more than 1 week in duration. The
return of neutrophil levels to >500 cells/mm3 is sufﬁcient to
place this type of patient in conventional rooms [77–79].
Whether to place other types of immunodepressed
patients, such as those receiving autologous stem cell hae-
matopoietic transplants or solid organ transplants, or those
undergoing prolonged intense treatment with steroids, in
rooms with a protected environment is an issue that has not
yet been decided. Hospitalization of this type of patient in
speciﬁc hospital areas may be of help in some circumstances,
such as during the initial phases of lung transplantation or
intense immunosuppressive treatment.
What cleaning and disinfection measures are recommended
in protected air facilities?
All rooms with patients at risk of IFI must be cleaned at least
twice daily and whenever there is accidental spillage of liq-
uids on the ﬂoor or surfaces. Cleaning must be carried out
with conventional disinfectants and following the manufac-
turer’s instructions. The use of cleaning tools that may cre-
ate dust or conidial aerosols is absolutely contraindicated in
any room within the premises of a health institution [77].
There is no evidence that special measures, such as the use
of fungicides or one-piece synthetic ﬂoor covering, reduces
exposure to Aspergillus conidia, although it is necessary to
follow the recommendations in the chapter on structures
used for prevention. Cleaning and disinfection of rooms with
patients at high risk for IFI, including protected environment
rooms with very high-risk patients, must be performed by
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conventional means, as other measures have not had any
demonstrable impact on the exposure of patients to fungi.
In protected environment areas, it is also necessary to
carry out regular preventive disinfection or sanitization, which
must include the disinfection of surfaces, installations, and the
general environment. There are no recommendations regard-
ing regularity, but these procedures should be carried out
whenever the number of particles in suspension or the CFU/
m3 in the air is above the recommended limits. Cleaning and
disinfection of surfaces must be deﬁned in the same hospital
protocols in which cleaning of facilities and treatment of air
and air conduits and circulation systems are addressed
[50,51]. Systems based on H2O2, also known as hydrogen
peroxide vapour systems, are very effective. Concentrations
>1 p.p.m. are not allowed in areas where there are people, so
the efﬁcacy of the system depends on the possibility of regu-
larly isolating areas for disinfection. Ozone systems are based
on the controlled injection of ozone into the environment
and the air treatment and circulation systems to achieve disin-
fection. For shock disinfectant treatment in areas with no
people, concentrations of 1 mg/m3 are used. For maintenance
and biological load reduction treatments in areas where there
are people, concentrations below 0.1 mg/m3 are used.
If there are water leakages from pipes or bathroom ﬁt-
tings near walls or ceilings in rooms with patients at risk for
IFI, it is necessary to rapidly ﬁx these leaks. Repairs must be
performed in <72 h to prevent the overgrowth of fungal
species on damp surfaces [77].
What measures should be taken when transferring patients
at risk from one area to another within the hospital?
As far as possible, movement of patients at high risk for IFI
from rooms with a protected environment must be restricted.
If they have to leave these rooms, for either diagnostic or
therapeutic reasons, they must not pass through hospital areas
where there may be high counts of conidia, such as areas
where refurbishment works are underway or where extraor-
dinary cleaning is being carried out. Furthermore, patients
must wear protective respiratory FFP3-type masks, except in
exceptional circumstances, and these must not be removed
when patients are outside the protected environment area
[77–79]. The use of portable X-ray machines seems not to
decrease the risk of IFI, and these can also be a source of con-
tamination, as they cannot be effectively disinfected.
What standard precautions must be taken to speciﬁcally
prevent IFIs?
The systematic use of certain standard precautions, such as
personnel clothing for exclusive use in protected environ-
ment areas, respiratory masks, and appropriate hand hygiene,
or the use of gloves, does not offer speciﬁc protection
against Aspergillus. However, most institutions follow these
recommendations in an attempt to decrease transmission
between patients or between health personnel and patients
of other microorganisms that cause infections in this type of
patient population [77].
What personal hygiene measures are recommended to
prevent IFIs?
With reference to the hygienic habits of patients at high risk
for IFI, especially recipients of transplants of haematopoietic
stem cells during the phase of severe or prolonged neutro-
penia, it is advisable to use single-use sponges for patient’s
daily body hygiene in their beds, and discourage the patients
from taking baths or showers [70,77–79].
The use of ﬁlters on the taps and in the showers seems
to control aerosolization of fungal conidia, even though there
are no data with which to carry out comparisons. These ﬁl-
ters must be regularly changed if they are to be used contin-
uously.
What measures should be taken if a new IFI case is
detected or if there is an IFI outbreak?
If a new IFI case is detected, the episode must be investi-
gated with the object of determining whether it was commu-
nity-acquired or related to hospitalization. If it is determined
that the case is of hospital origin, an in-depth analysis must
be performed, both retrospective and prospective, to iden-
tify the existence of new cases that might serve to character-
ize the outbreak. If any patients with IFI are detected, it is
indispensable to check the ventilation system and correct
any possible deﬁciencies [77,79].
If there is an outbreak, it is necessary to carry out the
appropriate epidemiological investigation and immediately
report the outbreak to the health authorities and public
health administrative agencies [77,79]. Environmental samples
must be taken, mainly of air, and occasionally of water, and
the presence of Aspergillus and other fungi investigated. A
molecular study of the species detected in patients and in
the environment may serve to identify the origin of the out-
break. Any defects in the ventilation systems must also be
identiﬁed and repaired as quickly as possible [77,79].
Special and additional preventive measures
What are the variations in the level of air contamination
with ﬁlamentous fungi in relation to structural work?
As mentioned above, there is no level of air contamination
with Aspergillus conidia that can be considered to be either
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normal or pathological. However, there is good evidence for
increases in the level of Aspergillus conidia during structural
work, both inside and in the vicinity of hospitals. The mean
concentration of fungi of the Aspergillus genus within hospitals
varies between 3 and 105 CFU/m3, according to the studies
reviewed [49,54,92–95]. Curtis et al. [96] carried out a 1-
year surveillance in a tertiary hospital while an extensive
refurbishment and demolition programme was being carried
out in the attached buildings. In this study, the authors saw
many peaks in the levels of ﬁlamentous fungi in air, as a con-
sequence of intervention or incidents related to the air ﬁltra-
tion system. Furthermore, demolition by controlled blasting
of a nearby building substantially increased the levels of coni-
dia in the air. In a study performed in Spain to determine
the impact of blasting a nearby building on the level of Asper-
gillus conidia in a hospital, it was seen that fungal counts in
the air during the days prior to blasting were 17.6 CFU/m3,
and these increased to 70.2 CFU/m3 with the wave of dust
caused by the demolition. These levels took almost 2 weeks
to return to baseline values [47]. There were no signiﬁcant
differences in conidial count between outside air and the
unprotected air within the hospital. On the other hand, most
of the protected areas with positive pressure and HEPA ﬁl-
ters had negative counts.
What is the evidence linking air levels of conidia with
invasive mycoses caused by ﬁlamentous fungi?
Although no level of contamination of air with Aspergillus has
been established as the baseline value, increases from which
would increase the risk of IA in an institution; increases in
conidial levels in the air correlate with increases in the inci-
dence of IA [97,98] and other IFIs caused by ﬁlamentous fungi
[99], usually related to refurbishment works in hospitals or
nearby areas [41,98,100,101]. Vonberg and Gastmeier [43]
carried out a systematic review in 2006 in which they included
all the outbreaks in an outbreak database, a register of hospital
outbreaks (http://www.outbreak-database.com), caused by
Aspergillus, from 1966 to 2005. In this study, there were 53
outbreaks that had affected 458 patients, most of them with
haematological cancer (65.3%). With the exception of one of
the outbreaks, contaminated air was the cause, and in most
patients, the lungs were the ﬁrst organs affected. Structural
work was the cause of almost half of the outbreaks seen.
Other indirect evidence is supplied by the protection of
patients hospitalized in rooms and areas with protected air
with HEPA ﬁlters and positive pressure [97,102–106]. A
recent study, published in 2007 by Benet et al. [107], showed
the protection provided by hospitalizing a large part of the
patient population in areas with protected air in comparison
with areas with conventional systems. Of 356 patients hospi-
talized in three haematology units during the study period,
21 developed IA. Originally, the three units did not have
HEPA ﬁlters. One of the units was relocated to another
module and equipped with barrier measures. The incidence
of aspergillosis in this unit went from 13.2% (nine patients)
before relocation to 1.6% (one patient, p 0.018) after reloca-
tion. The incidence of aspergillosis in the control group (the
other two units that were not refurbished) did not change.
The types of patient admitted to the three units were simi-
lar. Given this evidence, emphasis must be placed on the use
of protected environment rooms for patients at high risk for
IA, and on the need to perform counts in hospital areas
undergoing structural work or refurbishment. These counts
can also be of special use in unprotected environment areas
with patients at risk for mycoses. There are no data on
conidial levels that may be considered to be normal, but
concentrations >25 CFU/m3 are very high and are associated
with an increase in the number of cases of IA among patients
with risk factors.
How must structural work be classiﬁed on the basis of its
risk of causing high levels of conidia in air?
Structural work carried out inside and outside hospitals must
be stratiﬁed to adapt preventive methods to the degree of
risk associated with it, and also to determine what speciﬁca-
tions must be included in the contract. A classiﬁcation cur-
rently exists that was proposed by the Spanish Society of
Preventive Medicine; this is easy to apply, but it does not
include appropriate risk assessment. This classiﬁcation char-
acterizes work according to previous planning, and divides it
into scheduled and non-scheduled work [68]. Consideration
must also be given to the classiﬁcation laid down in the Pub-
lic Administration Contracts Act (Section 123), which classi-
ﬁes work according to its purpose (construction of a
building, repair, maintenance and demolition) and magnitude
(simple repair or major repair). However, the classiﬁcations
used by the Canadian and British Health Services are more
useful when planning preventive measures. The Canadian
Health Service [78] deﬁnes four levels of activity, from one
considered to be a minor risk to large demolitions or recon-
struction projects, and evaluates the risk of these on the
basis of a check-list. The elements assessed are, among oth-
ers, the amount of dust produced and the possibility of pre-
venting it from leaving the site or spreading, the duration of
the work, whether ﬁxed building components are cut, chan-
ged or demolished, and any plumbing works. This classiﬁca-
tion distinguishes between short-term and long-term
activities, depending on whether they take one working day
or more, but does not take into account factors such as the
number of workers required to carry out the work or to
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move material and people. Table 6 shows the classiﬁcation
of work according to the Canadian system.
What preventive action should be taken according to the
category of work?
The decision on the measures to be taken when any work is
carried out in a hospital must be made in a collegiate manner
by a multidisciplinary group, normally an integral part of the
Works Committee, which must work with the Committee
for the Control and Evaluation of the Risk of Infection. The
risk evaluation study carried out beforehand must clearly
deﬁne the magnitude of the work and the risk that it
involves, according to what has been detailed above. The
population at risk for IFI can be subdivided into groups
(Group 1, low risk; Group 2, medium risk; Group 3, high
risk; and Group 4, maximum risk; this is the population nor-
mally hospitalized in a protected environment).
The prevention protocol must detail different characteris-
tics, such as the location of the work, its starting date, and
its estimated duration. The names of the person responsible
for the work, the contractors and the professional belonging
to the health institution responsible for infection control
must all be written down. The document must include the
telephone numbers of the responsible parties, so that there
may be ﬂuid communication between them.
The measures to be applied must be classiﬁed into classes
(I–IV) according to their intensity, and responsibility must be
apportioned correspondingly among the members of the
multidisciplinary group. In the case of class I measures, the
workers must immediately replace lifted paving and other
material, and vacuum and clean up the dust produced. The
plumbers must programme water cuts for off-peak periods,
drain air from the pipes before reconnecting the water, and
check the colour of the water. They must also make sure
that water achieves the correct preset temperature, keep
the surrounding areas as dry as possible, and report and
repair water leaks that wet walls and ﬂoors. The surveillance
services personnel must report water leakages or the pres-
ence of non-transparent water to maintenance and infection
control. Health personnel must minimize patient exposure to
areas where works are underway, and also report the pres-
ence of non-transparent water to maintenance.
In the case of class II measures, workers must control
dust, carry out their tasks with measures to raise as little
dust as possible, use wet cloths, vacuuming or water blankets
to minimize dust dispersion, and seal doors and windows
with adhesive tape. Anti-dust carpets must be laid at the
entrance to the working area, and this must be physically
closed off. Ventilation in the area where the works are being
carried out must be deactivated to prevent dust dissemina-
tion. The need to change air ﬁlters in the area where con-
struction or refurbishment took place must be evaluated.
The rubble must be removed in closed containers covered
with wet blankets. The plumbers must prevent water from
remaining in pipes or puddles. Surveillance and cleaning ser-
vices personnel must use wet cloths to clean and HEPA ﬁl-
ters to vacuum as necessary when the work is ﬁnished.
Furthermore, ﬂat surfaces must be cleaned with disinfectant.
Health personnel must identify high-risk patients who may
need to be moved to other rooms or areas far from the
construction work. Furthermore, it is necessary to ensure
that the equipment and material necessary to care for the
patients is stored in areas protected from exposure to dust.
In the case of class III measures, the workers must make
sure that the works protocol has been completed and
approved by the Committee after consulting all those
involved. A dustproof barrier must be erected, from ﬂoor to
ceiling. They must ensure that windows, doors, pipe entries,
air intakes and outlets and other places that could potentially
allow the entry of dust are appropriately sealed with adhe-
sive tape. The dust from air conduits and the spaces above
ceilings must be vacuumed if necessary. Workers in the con-
struction area must wear clothing that is removed when they
leave their work area and that they do not wear when mov-
ing through areas where there are patients. The mechanical
barrier must not be removed until the project is ﬁnished,
the rubble has been removed, and the area has been cleaned
and inspected. The mechanical barrier must be removed with
TABLE 6. Types of structural work according to the Canadian Health System
Types of
work Characteristics
Type A Activities that do not generate dust in principle. These include activities such as removal of roof panels for visual inspection (limited to the opening of not
more than one panel of each 50 m2 of roof), painting (without sanding), wallpapering, electricity work, small-scale plumbing work, and other maintenance
activities that take little time, do not raise dust, and do not require openings in walls or substantial access to under-roof areas
Type B Small-scale work of short duration that generates little dust. Access to drainpipes, small demolition activities in which the amount of dust may be
controlled, plumbing work that requires water cuts to two or more rooms for <30 min, laying of telephone or power cables
Type C Any procedure that generates moderate to large quantities of dust or that requires demolition or refurbishing of building components. Usually, this is
deﬁned as work that cannot be ﬁnished during one work-shift and that includes activities such as changing of carpets or rugs, demolition of walls, large
cable-laying procedures, and plumbing work that requires water cuts to more than two rooms for >30 min but <1 h.
Type D Major demolition, construction and refurbishing projects. Including, but not limited to, activities such as demolition, partition building, large cable-laying
operations, and plumbing work that requires water cuts of more than 1 h
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care, minimizing any dust production. Regarding ventilation,
negative pressure must be maintained in the construction
area with portable HEPA ﬁlters, ensuring that the air in the
area where work is underway is eliminated far from air inlets
or that it is ﬁltered through HEPA ﬁlters before it is recircu-
lated, and ensuring that the ventilation system is functioning
appropriately and that the ﬁlters are cleaned. Moreover, any
rubble or debris must be removed at the end of each work-
day, an external hopper must be used if the work is at
ground level, and the area of the work must be vacuumed
daily with vacuum systems that use HEPA ﬁlters. The plumb-
ers must drain all pipes in the areas where there are patients
before these return to their rooms. Surveillance services
personnel must inspect the dust barriers and design routes
for the construction workers to use, so that there is no
movement from dirty to clean areas where there are
patients. Health personnel must move high-risk patients away
from areas near the work, ensure that patients do not go
near the working area, and check that this area is appropri-
ately cleaned when work ends.
Class IV measures include the erection of an impermeable
barrier by the workers with an antechamber to provide fur-
ther protection from dust, before the project is begun. Anti-
dust carpets must be placed at the entrance and exit of the
area where work is ongoing, to prevent the contamination
of footwear. Workers must leave the work area through the
antechamber, so that they may be vacuumed with a system
with HEPA ﬁlters before leaving the work area. Personnel
entering the construction zone must use disposable shoe-
covers. If holes are made in walls, these must be repaired
within 8 h or temporarily sealed off. Negative pressure must
be maintained in the antechamber and the construction zone,
and ventilation systems must be functioning in the adjacent
areas and construction area. Surveillance services personnel
must regularly control protection measures and also perform
controls at the end of the project. Health personnel must
review all of the measures included in the protection plan
with all the members of the Committee during the project
and when it is ended, and determine their efﬁcacy. Health
personnel should not enter the area where work is ongoing.
The plan for each project must have a table diagram, such
as that in Table 7, with details of the measures to be taken
(I–IV), according to the type of project (A–D), and the risk
for patients (1–4).
Preventive measures outside hospitals
The recommendations aimed at preventing fungal infections
outside hospitals in immunodepressed patients have not been
assessed in studies with an adequate design; therefore, it is
difﬁcult to use them for classiﬁcations with any level of scien-
tiﬁc evidence. These recommendations are based on hospital
practices and adapted to patients’ everyday life outside
health institutions [77,79].
Who are the members of the community at risk for
acquiring IFIs?
The factors involved in the risk of suffering from IFI are
complex. The main one is neutropenia induced by chemo-
therapy in patients who go home during the aplasia period.
There are also other conditions that increase risk, such as
the presence of a central venous catheter, ambulatory paren-
teral nutrition, colonization by yeasts, and immunosuppres-
sive treatment [3,8,9,11,14,36]. Patient subgroups at high risk
for IFI are outlined in the epidemiology section. Regarding
risk in ambulatory patients, it is necessary to mention
patients with neutropenia who are being treated with che-
motherapy for AML or MDS who go home during the aplasia
period. The incidence is approximately 10–25% [9,11,14].
The use of purine analogues as part of some ambulatory che-
motherapy regimens in different haematological conditions is
also associated with a greater risk of IFI. Patients undergoing
allogeneic haematopoietic stem cell transplantation [9] also
suffer a high incidence, which may reach 10–25% in cases of
non-related transplants or umbilical cord transplants.
Another group of patients at risk for IA are those with
chronic respiratory conditions and prolonged use of steroids,
especially those receiving high doses (>20 mg/day or cumula-
tive doses of 700 mg), although cases have also been
reported in patients receiving high doses of inhaled steroids
[19], and also in other immunodepressed patients (solid
organ transplants or liver cirrhosis) or in patients who have
undergone treatment with monoclonal antibodies [24].
What environmental factors affect this risk and should be
avoided?
Aspergillus is a fungus that is normally in the environment,
and is frequently inhaled. Therefore, persons at risk for IFI
must be prevented from going to places where the number
TABLE 7. Table diagram that summarizes the measures to
be taken according to the type of work and infection risk
group
Risk group
Degree of intensity of the work
Type A Type B Type C Type D
Group 1 I II II III/IV
Group 2 I II III IV
Group 3 I III III/IV IV
Group 4 I–III III/IV III/IV IV
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of conidia is greater than usual, such as construction or
refurbishment areas, and areas where gardening is being car-
ried out [77–79,108].
There are several additional sources of conidia, such as
dust that settles on ﬂoors and ﬂat surfaces, ornamental
plants and elements of decoration such as carpets, curtains,
and cushions. Therefore, the patient’s home must be
cleaned, and contact with these elements must be avoided,
as much as possible. Special care must be taken with paediat-
ric patients with regard to toy control and cleaning, espe-
cially in the case of ﬂuffy toys.
Regarding the hygienic habits of patients at high risk for
IFI, especially recipients of transplants of haematopoietic
stem cells with severe and prolonged neutropenia, they must
be advised to use individual sponges and personal hygiene
products [77,79].
Inhalation of tobacco smoke or cannabis and/or marihuana
smoke has been associated with pulmonary IA in immunode-
pressed patients, so smoking of any kind is forbidden in
these patients.
Pets may also transport ﬁlamentous fungi conidia and be a
source of infection. There are no speciﬁc recommendations
on IFI transmitted by pets, but there are general recommen-
dations on the prevention of zoonoses, and on infection pre-
vention measures for immunodepressed patients who have
pets [109–112]. To prevent infections transmitted by pets,
simple behaviour and personal hygiene rules must be fol-
lowed. As a general rule, when a patient is living with or
coming into contact with pets, hands must be washed fre-
quently and no objects must be placed near the mouth
(pens, toys, etc.). After the patient has been feeding or play-
ing with pets, hands must be washed. It is necessary to avoid
sitting, lying or playing in places contaminated with dog and
cat droppings. Finally, direct contact with infected animals
must be avoided.
What invasive procedures can inﬂuence
community-acquired IFI?
It is not usual for patients to undergo invasive procedures at
home that might increase the risk of IFI. If a procedure is
carried out, such as a change of catheter, urethral catheter,
nasogastric tube or bandages on wounds, hand hygiene, asep-
sis and barrier methods such as sterile gloves, gowns and
masks are recommended [77,79].
When the sick are being cared for, hands are the main
vehicles of transmission of pathogens, either by direct per-
son-to-person contact or by indirect contamination with pre-
viously contaminated objects. Hand hygiene is a simple
action and must be practised by all those who care for a
patient, whether health workers or carers.
Can diet inﬂuence the risk of IA?
During their stay in health institutions, the food given to
patients at very high risk of acquiring opportunistic infections
is rigorously controlled. The main recommendations are not
to eat raw or uncooked food, to avoid eating food with an
unknown bacterial load, to avoid unpeeled fruit, and not to
add ice-cubes to drinks [77,79]. These recommendations are
made to avoid opportunistic infections of bacterial origin,
and their role in the prevention of infections by fungi is not
known. Certain foods, such as spices, tea, other herbs used
for infusions, non-pasteurized beer, aromatic herbs, fresh or
dry, which have not been cooked for several minutes, blue
cheeses or those that have undergone prolonged fermenta-
tion processes, may contain high concentrations of ﬁlamen-
tous fungi, and are therefore totally forbidden in patients at
risk for IFI.
What conditions should a patient’s home comply with to
decrease the risk of IFI?
The recommendations on the environmental conditions for
patients at risk for IFI aim to ensure levels of air quality and
cleanliness that prevent, as much as possible, the presence of
conidia in inhaled air. Most patients’ homes comply with con-
ditions that probably reduce the danger of transmission of
these pathogens to low levels. However, it is important that
both patients and their families be informed and educated on
necessary basic standards.
Home air-conditioning may be achieved with conventional
air-conditioners for home use, because, in general, patients
are not connected to a general air-conditioning network, and
there is therefore is no risk of conidia reaching them
through air distribution circuits. Regular maintenance of
equipment is advisable, especially changes of particle ﬁlters
[77,79].
Recommendations must be made that no work, refurbish-
ment or gardening be performed in the patient’s home while
they are at risk of contracting IFI. If these are unavoidable
and the patient cannot be moved elsewhere while they take
place, appropriate masks (FFP3) must be recommended, if it
is considered that there is a high potential risk.
Flat surfaces in the patient’s home must be regularly
cleaned, and all dirt and dust eliminated. Fungi are usually
present in environmental air, although they may spread from
ﬂat surfaces where there is dust and persistent dampness.
Therefore, it is advisable that the use of environmental clean-
ing systems that cause dust be avoided, e.g. conventional vac-
uum cleaners, owing to their potential for creating conidial
aerosols. However, vacuum cleaners with HEPA ﬁlters may
be used. Persistent dampness in walls and ceilings must be
rectiﬁed as soon as possible. There should be no carpets
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and rugs in use, as these act as storage places for large quan-
tities of dust. Flat surfaces can be cleaned with soap or
detergents and water, with an interval that depends on the
degree of dirt that accumulates, although two to three times
a week as a minimum is recommended. Regarding ornamen-
tal plants and pets, the recommendations detailed above
must be applied.
Water can also be a source of fungal conidia. There is no
agreement on whether home water ﬁlters should be used,
but it is acknowledged that ﬁttings should be carefully
cleaned and bleach used on them. Shower curtains should
not be used, as they are fungal reservoirs. The patient should
not have access to covered pools or recreational public or
private pools, where there may be water aerosolization, dur-
ing risk periods for IFI.
Should environmental controls be put in place outside
hospitals?
Detection and quantiﬁcation of conidia of Aspergillus in the
air and water outside hospitals is a subject that has not been
well studied. Recently, an extensive study was published on
an area in Madrid in which it was determined that high levels
of conidia can exist (up to 85 CFU/m3) in the air, with a pre-
dominance of A. fumigatus, although there was an absence of
these in water [44]. The clinical signiﬁcance of these values is
not known, so no recommendations can be made on the
basis of them, and neither can they be related to regular sur-
veillance of the levels of environmental colonization or mea-
sures to protect patients at risk of contracting aspergillosis.
Pharmacological prophylaxis
Above, we have listed recommendations for preventing
patients at risk for IFI from acquiring the infection. However,
some groups of patients, with a very high risk, must also
receive antifungal drug prophylaxis. It is not possible to carry
out an in-depth review on antifungal prophylaxis in this docu-
ment, as it is not one of the objectives of these recommen-
dations. We do not include the levels of evidence on which
these recommendations are based, and we therefore advise
readers to consult speciﬁc guides on antifungal prophylaxis.
What groups of patients with haematological diseases
should receive prophylaxis with drugs for the prevention of
invasive mycoses caused by ﬁlamentous fungi?
Different clinical trials have shown that prophylaxis with
ﬂuconazole [113–118] reduces the number of mycoses and
increases the survival of haematopoietic stem cell transplant
recipients and those undergoing intensive chemotherapy for
malignant haematological conditions. However, because of
its selective action on yeasts, the use of prophylactic ﬂuco-
nazole has no impact on the incidence of IFI caused by ﬁla-
mentous fungi. Therefore, during this decade, with the
appearance of wide-spectrum azoles (itraconazole, vorico-
nazole and posaconazole), the scientiﬁc community has
addressed the issue of the need for prophylaxis for condi-
tions caused by ﬁlamentous fungi in certain high-risk patient
cohorts [119].
Whether antifungal prophylaxis is appropriate or not
depends on cost, efﬁcacy, interactions, toxicity, resistance
generation, and the incidence of IFI in each clinical situation.
The incidence of IFI caused by ﬁlamentous fungi ranges from
0.5% in patients undergoing autologous transplantation to
14% in patients with active GVHD in allogeneic transplants,
with 4.3% in acute lymphoblastic leukaemia patients and 7.9%
in AML patients [36,120]. Table 8 summarizes the different
recommendations of scientiﬁc societies, standard practices in
some large centres and the main publications on primary
antifungal prophylaxis in patients with haematological
conditions. Regarding secondary prophylaxis, there is little
evidence in the literature, although most centres use prophy-
laxis for ﬁlamentous fungal diseases in patients with a history
of IFI when they present some new risk factor.
TABLE 8. Summary of the recommendations on primary antifungal prophylaxis in haematological patients
Blood disease patient Yeasts Filamentous fungi Duration of prophylaxis
AML/MDS Induction treatment Yes Yes RAN > 1000/lL
Consolidation/intensiﬁcation treatment Yes ?a RAN > 1000/lL
ALL With prolonged steroid treatmentb Yes ?a PDN < 0.5 mg/kg/day
Without prolonged steroid treatmentb Noa Noa RAN > 1000/lL
Autologous transplant patient With mucositis grade ‡2 (WHO) Yes Noa Day + 30
Without mucositis grade ‡2 (WHO) Noa Noa Day + 30
Allogeneic transplant patient With active GVHD Yes Yes Control of GVHD
Steroid treatment Yes Yes PDN £ 0.5 mg/kg/day
Without active GVHD or steroid treatment Yes ?a Day + 75
ALL, acute lymphoblastic leukaemia; AML, acute myeloblastic leukaemia; GVHD, graft-versus-host disease; MDS, myelodysplastic syndrome; PDN, prednisone; RAN, neu-
trophils in blood; ?, insufﬁcient data.
aUnless RAN < 100/lL for >2–3 weeks or there is another added invasive fungal infection risk factor.
b>1 mg/kg/day for >1 week (if RAN < 1000/lL) or >2 mg/kg/day for >2 weeks (independent of RAN).
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What drugs should be used in haematological patients and
how should they be administered?
IFI prophylaxis has been carried out with polyenes, candines
and, especially, wide-spectrum triazoles. Non-absorbable oral
antifungals (amphotericin B, nystatin and clotrimazole solu-
tions) may reduce fungal colonization of mucous membranes
and intestines. However, these drugs have not been shown to
prevent the development of local fungal invasion or IFI, and
they are therefore not recommended as prophylaxis [121].
Intravenous amphotericin B, both conventional and lipid
forms, in low or intermediate daily doses or high doses in
pulse form, has been shown to be useful as prophylaxis for
IFI [122–126]. However, the results of these studies have
not achieved sufﬁcient levels of evidence for this strategy to
be considered the treatment of choice for primary prophy-
laxis [127]. On the other hand, in a recent randomized pla-
cebo-controlled study, inhaled liposomal amphotericin B
reduced the incidence of pulmonary IA in patients with neu-
tropenia and haematological conditions [128].
Micafungin, on the basis of a study in which non-inferiority
in relation to ﬂuconazole was demonstrated, is indicated in
invasive candidiasis in allogeneic transplant patients or in
patients expected to develop profound neutropenia
(<500 neutrophils/lL) over the course of ‡10 days
[129,130]. There is not sufﬁcient evidence on the use of can-
dins as ﬁlamentous fungal IFI prophylaxis, so these drugs
should not be used for this purpose in patients with haema-
tological conditions.
Itraconazole in capsules should not be used as IFI prophy-
laxis, owing to the variable and deﬁcient bioavailability of the
drug in this form. On the other hand, itraconazole in oral or
intravenous solutions has been shown, in different studies, to
be effective for the prevention of ﬁlamentous fungal IFI,
reducing the incidence and mortality of this infection [131–
134]. These and other studies have shown that itraconazole
is more effective than ﬂuconazole in the prevention of IFI in
high-risk patients, but side effects, usually gastrointestinal,
limit its use. The guidelines of the National Comprehensive
Cancer Network (NCCN), the Infectious Disease Society of
America (IDSA) and the European Conference on Infections
in Leukaemia (ECIL) recommend the prophylactic use of itr-
aconazole in patients with allogeneic transplants with levels
of evidence of category 1, 1 and BI, respectively [135–137].
Itraconazole in oral solution is approved in Spain as IFI
prophylaxis in infections that are sensitive to itraconazole
and when standard treatments are not considered to be
appropriate, and in patients with haematological neoplasias
or with transplants that are expected to suffer pronounced
neutropenia (<500 neutropohils/lL) [138]. Patients must be
given oral itraconazole solutions on an empty stomach to
achieve adequate absorption of this drug, and if tolerance is
not good, it must be replaced by another drug.
Voriconazole, because of its spectrum and favourable
safety proﬁle, could be equally effective and better tolerated
than itraconazole in cases of ﬁlamentous fungal IFI. The
NCNN and IDSA consider that prophylactic use of vorico-
nazole presents a level of evidence/category of BII in AML/
MDS and in patients with allogeneic transplants [136,137].
Currently, this drug is not approved for this indication in
our country.
Posaconazole, which is currently only available in oral
solution, has been shown in recent randomized controlled
studies to have high efﬁcacy and an excellent safety proﬁle in
the prophylaxis for IFI in high-risk patients. The ﬁrst study
included patients with AML or MDS, treated with intensive
chemotherapy. Half of the patients received oral posaconaz-
ole, and the other half itraconazole or ﬂuconazole. The posa-
conazole arm had a lower incidence of IFI (2% versus 8%;
p <0.001) and IA (1% versus 7%; p <0.001). IFI-related mor-
tality was signiﬁcantly lower with posaconazole. The percent-
age of adverse effects was similar in both treatment groups
[12]. The other study included patients who underwent allo-
geneic transplants with GVHD. Half of the patients received
oral posaconazole, and the other half itraconazole or ﬂuco-
nazole, for 16 weeks. The global incidence of IFI tended to
be lower in the posaconazole group, without these numbers
reaching statistical signiﬁcance. However, IFI incidence during
treatment, IA incidence and the incidence of breakthrough
infections were signiﬁcantly lower in patients receiving posa-
conazole. IFI-related mortality was also lower in the posaco-
nazole arm. The adverse effects proﬁle was similar in both
groups [139]. The NCNN and IDSA recommend the admin-
istration of prophylactic posaconazole in AML/MDS patients
and in allogeneic transplant patients with GVHD (category/
level of recommendation 1) [136,137]. ECIL guidelines rec-
ommend this prophylactic treatment in patients with acute
leukaemia treated with induction chemotherapy and in
patients with allogeneic transplants with an A1 level of
evidence [135]. Posaconazole is approved in Spain for IFI
prophylaxis in patients receiving remission–induction chemo-
therapy for AML or MDS who are expected to develop pro-
longed neutropenia and who are at high risk of developing
IFI, and in patients who are transplant recipients and are on
high doses of immunosuppressants for GVHD and who are
at high risk of developing IFI [140].
When and for how long should prophylaxis be administered
in patients with haematological conditions?
The optimum duration of antifungal prophylaxis for ﬁlamen-
tous fungal infection is not completely clear, and depends on
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underlying risk factors [141]. Therefore, patients with neu-
tropenia should receive prophylaxis until their neurophil lev-
els are >1000/lL, and, in patients with active GVHD, until
this is controlled and the steroid dose is £0.5 mg/kg/day of
prednisone (Table 8).
Which patients with non-haematological diseases are
candidates for prophylaxis to prevent IFIs caused by
ﬁlamentous fungi?
Solid organ transplant recipients and a heterogeneous group
of other immunodepressed patients who do not suffer from
haematological diseases are also at risk for IFI caused by ﬁla-
mentous fungi.
Because of advances in the use of immunosuppressive ther-
apy, patients who are solid organ recipients currently have
better survival rates. Similarly, mortality of infectious origin
has substantially decreased, although infectious complications
still represent one of the major causes of death in these
patients [142]. The IA incidence is high in patients who have
undergone lung, heart and intestine transplantation, and
reaches levels of 6–14%, according to the prophylaxis used
[143]. In lung transplant recipients, IA can present in two
well-differentiated ways, according to the post-transplantation
time elapsed. During the early period, airway infections pre-
dominate, such as ulcerative tracheobronchitis and bronchial
anastomosis infections. Disseminated and pulmonary infec-
tions are more frequent in the late post-transplantation per-
iod, and are seen in patients with chronic rejection [144,145].
In liver transplant recipients, a recent national study
reported an incidence of 2.8% [14]. However, in high-risk
patients (renal failure, renal clearance techniques, re-trans-
plants, or re-operation), this incidence may be as high as
20% [13]. A lower incidence (<1%) is seen in renal transplant
recipients [13–15,143].
On the other hand, there is a heterogeneous group of
patients at risk for IFI whose immunosuppression status is
not related to solid organ transplantation and who have been
described in the ﬁrst part of these recommendations. These
are the patients suffering from AIDS who do not receive
high-activity retroviral treatment, patients with large burns,
and critically ill patients [23,25,146,147]. In these patients,
the conditions causing immunosuppression are many; among
them, malnutrition, COPD, liver failure and steroid adminis-
tration can be highlighted. Congenital immunodeﬁciencies
cause the greatest incidence of IFI in children. Patients with
Wiskott–Aldrich disease may suffer an incidence of IFI of
30%, and those with chronic granulomatous disease an inci-
dence of 6.5% [16,148].
Therefore, prophylactic strategies can be useful in these
types of patient at high risk of contracting IFI caused by ﬁla-
mentous fungi. However, to date there is only evidence that
prophylaxis is a useful strategy in recipients of lung trans-
plants, certain high-risk recipients of other solid organ trans-
plants, and patients with inherited immune disorders, e.g.
chronic granulomatous disease.
What drugs must be administered to patients with
non-haematological conditions and by what route?
Non-randomized studies with amphotericin B in aerosol
form as prophylaxis in lung transplant recipients have shown
discordant results, owing to design limitations and patient
selection. However, the efﬁcacy of this polyene was shown
to be 92% [149–151]. This route of administration avoids
systemic side effects and drug interactions. The administra-
tion of 25 mg of liposomal amphotericin B was effective in
achieving protection of patients with lung transplants from
infection by Aspergillus over a 15-day period, without any sys-
temic absorption being detected and without any ill-effects
on lung function [150]. In a clinical trial with 104 patients
who received prophylactic liposomal amphotericin B in nebu-
lized form, only two episodes of IFI were diagnosed (1.9%)
[152]. The administration of amphotericin B lipid complex in
nebulized form, at a dose of 50 mg every 2 days for the ﬁrst
3 weeks and once weekly thereafter, has also been shown to
be effective in this population [151,153].
Another option is the administration of voriconazole. In a
non-randomized study of 95 lung transplant patients, this
drug reduced the incidence of IA to 1.5% and that of fungal
infections caused by other fungi to 3% [154]. However, liver
toxicity was seen in up to 60% of patients, and 14% aban-
doned the use of prophylaxis with this drug, owing to its
side effects. Close surveillance of anticalcineurin drug con-
centrations must be carried out, given that voriconazole
inhibits the metabolism of those drugs. To avoid these prob-
lems, studies are being carried out with voriconazole by
inhalation in murine animal models [155].
Prophylaxis with amphotericin B deoxycholate in liver
transplant patients is not effective at low doses (0.5 mg/kg/
day), and at higher doses causes severe secondary effects,
such as reactions to infusions, nephrotoxicity, and metabolic
disorders. On the other hand, lipid formulations have
decreased nephrotoxicity and infusion reactions. A prospec-
tive randomized study with liposomal amphotericin B at a
dose of 1 mg/kg/day for 5–10 days was shown to reduce the
number of invasive mycoses in general, but not of IA in par-
ticular [156]. Other studies with historic controls suggest a
protective association between the use of liposomal ampho-
tericin B and IFI in liver transplant receptors [157,158]. In
another study, patients with an ICU stay of more than 5 days
who received different doses of liposomal amphotericin B
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showed identical results [159]. Therefore, it is advisable to
administer this drug to certain patients in a targeted manner
for a variable period of time related to the duration of risk
factors (Table 9) [160].
Itraconazole was evaluated in a prospective trial in liver
transplant recipients, and showed limited efﬁcacy [161].
However, in high-risk recipients of heart transplants (isola-
tion of Aspergillus in respiratory samples, re-operation, renal
clearance techniques, CMV disease), administration of this
drug at doses of 400 mg/day from the ﬁfth day to the thirrd
or sixth month was associated with a lower incidence of dis-
ease [162]. Furthermore, in chronic granulomatous disease,
itraconazole administered for 1 year at a dose of 200 mg/day
was shown to be effective in preventing IA [163].
A recent multicentre, open, non-comparative study of ca-
spofungin, administered for 21 days, assessed its IFI prophy-
laxis potential in high-risk liver transplant receipients. Of
the 71 patients in the study, two developed IFI, one caused
by Mucor and the other by Candida albicans. Grade IV liver
enzyme alterations were seen in 27.7% of the patients, and
this caused abandonment of prophylaxis in six patients
[164].
In patients with solid organ transplants who have late risk
factors, such as haemodialysis, infection relapse caused by
hepatitis C virus, or chronic rejection, long-term prophylaxis
is necessary, so the use of parenteral medication is not rec-
ommended, because of problems related to the route of
administration and adverse effects. In these cases, other
routes of prophylaxis administration could be more appro-
priate, such as lipid amphotericin B in nebulized form.
At what time and for how long should non-haematological
patients receive prophylaxis?
In patients with lung transplants, a period of 4 months could
be sufﬁcient if there is resolution of bronchial sutures, no
rejection, no alveolar damage and no CMV infection or
excess immunosuppression. However, lipid amphotericin B in
nebulized form may be given indeﬁnitely, because of the risk
of late infection and its potential beneﬁts as prophylaxis.
In recipients of other kinds of solid organ transplant, pro-
phylaxis must be administered when risk factors appear, and
must continue while these are present [165]. Table 9 dis-
plays a summary of the recommendations for prophylaxis
against IFI caused by ﬁlamentous fungi in patients at risk.
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TABLE 9. Prophylaxis regimen for ﬁlamentous fungi in high-risk patients
Indication Target population Antifungal drug Duration Observations
Lung transplant
patient
All Liposomal amphotericin B 25 mg
or amphotericin B lipid complex
50 mg, in nebulized form, three
times weekly until resolution of
bronchial suture, once a week
from the second to the sixth
month, and once a fortnight from
the sixth month on
Indeﬁnite Bronchospasm as a side effect
Voriconazole 200 mg/12 h orally Determined by the presence
of risk factors, although it is
usually administered for a
minimum of 4 months
Monitor liver enzymes, voriconazole
concentrations, and anticalcineurins
Other solid organ
transplant patients
High-risk patients for early IFI:
renal clearance techniques,
CMV disease, acute liver
failure (liver transplant),
primary graft failure,
re-transplantation
Amphotericin B lipid formulation
2.5–5 mg/kg/day parenterally
Determined by the presence
of risk factors
Studies carried out preferably in liver
transplant patients
Itraconazole 400 mg/day orally Study carried out in heart transplant
patients. Monitor anticalcineurin
concentrations
Caspofungin 70 mg/day in the ﬁrst
dose and then continue with
50 mg/day
Study carried out in liver transplant
patients. Monitor liver enzymes. In
the study, this was administered for
21 days
High-risk patients for late IFI:
chronic rejection, recurrent
liver condition VHC (liver
transplant), renal clearance
techniques
Liposomal amphotericin B 25 mg
or amphotericin B lipid complex
50 mg, in nebulized form three
times weekly until resolution of
bronchial suture, oncea\ week
from the second to the sixth
month, and oncea fortnight from
the sixth month on
Bronchospasm as a side effect
Chronic
granulomatous disease
Patients over 5 years of age Itraconazole 200 mg/day orally
(100 mg/day <13 years or <50 kg
of weight)
Indeﬁnite In the clinical trial, prophylaxis was
carried out for 1 year
CMV, cytomegalovirus; IFI, invasive fungal infection; VHC, virus of hepatitis C.
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